Jan. 15, 2009--Orion Corporation filed a patent infringement lawsuit in the United States to enforce U.S. Patent Nos. 5,135,950; 5,446,194; and 6,500,867 against Wockhardt USA LLC and Wockhardt Limited, who seek to market generic versions of Orion Corporation's proprietary drug, Stalevo® (specifically 25/200/100 mg, 37.5/200/150 mg, and 50/200/200 mg strengths of carbidopa/entacapone/levodopa) in the United States. Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee, Novartis, for the treatment of Parkinson's disease.
The details can be read here.
No comments:
Post a Comment